Enhancing Access to Pheburane® for Rare Disease Patients
Medunik USA, a dedicated specialty pharmaceutical company, is making significant strides in ensuring that patients suffering from rare diseases have access to critical medications. The company focuses on orphan drugs meant for the treatment of rare conditions, and it is part of the Duchesnay Pharmaceutical Group (DPG). Recently, Medunik USA announced that Pheburane® (sodium phenylbutyrate) is now covered under Preferred Medicaid Programs in 19 states. Furthermore, 29 states provide it under Medicaid Programs with limited or no restrictions, greatly improving accessibility for those in need.
Pheburane®: A Crucial Therapy
Pheburane® is an effective adjunctive therapy for managing certain urea cycle disorders (UCDs), which require dietary management as part of the standard care protocol. This innovative formulation consists of small, palatable coated pellets that are easy for both adult and pediatric patients to ingest. It's important to note that while Pheburane® is an essential component of treatment for many individuals, it is not indicated for the treatment of acute hyperammonemia. Side effects can include decreased appetite, body odor, menstrual dysfunction, and taste aversion, though these effects are often manageable.
Commitment to Patient Support
Tanya Carro, Executive Vice President of U.S. Entities at Medunik USA, expressed their unwavering commitment to providing support to individuals affected by rare diseases. "Patients suffering from these conditions deserve access to effective therapeutic options just as much as those with more common ailments do," she stated. The company’s dedication extends beyond medication; they are committed to offering robust patient support through their UNIK Support Program.
Understanding the UNIK Support Program
This comprehensive support program is designed to address the unique needs of each patient, offering personalized assistance throughout their treatment journey. Key features of the UNIK Support Program include:
- Personalized Clinical Coordinator Outreach Program that assists patients with tailored guidance.
- Copay and Patient Assistance Programs designed to alleviate the financial burden, enabling eligible patients to pay little to nothing out of pocket.
- Mail Order Pharmacy Services that provide home delivery through specialized national pharmacies while assisting with copay and financial assistance program enrollment.
- Quick Start & Bridge Program facilitating immediate access to Pheburane®, enabling patients to begin treatment without delay as insurance approvals are resolved.
The Importance of Coverage Expansion
With the prevalence of UCDs estimated at one in every 35,000 individuals in the United States, the expansion of Pheburane® availability through Medicaid and patient support programs represents a major advancement in addressing healthcare disparities for those affected by rare diseases. By enhancing coverage, Medunik USA can help ensure that more individuals can receive the necessary treatment without financial hardship.
About Urea Cycle Disorders
Urea Cycle Disorders are genetic conditions that hinder the body's ability to remove toxic ammonia from the bloodstream, putting patients at risk of severe health complications. Symptoms can appear within days after birth, and individuals often require lifelong management to prevent potential health issues. The timely access to medications such as Pheburane® is essential for these patients.
About Pheburane®
Pheburane® serves as a crucial adjunctive treatment for both adults and children with UCDs. The formulation reduces the toxicity associated with elevated ammonia levels while integrating dietary management as part of a comprehensive treatment protocol. Notably, Pheburane® is not designed for use in acute hyperammonemia, emphasizing the importance of understanding its proper application in patient care.
Understanding Side Effects and Safety
As with any medication, it is essential for healthcare providers to monitor patients for potential side effects when using Pheburane®. Common concerns may include low potassium levels and effects related to swelling, making it vital for patients to maintain open communication with their healthcare teams.
Next Steps for Patients
Patients interested in learning more about Pheburane® or the UNIK Support Program can reach out for personalized guidance. The commitment of Medunik USA to support patients through their treatment journeys shines through in their ongoing efforts to expand access to vital medications that can improve their lives.
Frequently Asked Questions
What is Pheburane® used for?
Pheburane® is an adjunctive therapy for managing urea cycle disorders, helping to reduce toxic ammonia levels in the blood.
Who can benefit from the UNIK Support Program?
The program is designed to support patients with rare diseases, offering various resources to help manage treatment costs and access medications.
How does Medunik USA ensure patient access to medications?
By expanding Medicaid coverage and providing tailored support options through their programs, Medunik USA strives to make treatments like Pheburane® widely accessible.
What are the main side effects of Pheburane®?
Common side effects include decreased appetite, taste aversion, body odor, and menstrual dysfunction, which should be discussed with a healthcare provider.
Is Pheburane® suitable for all ages?
Pheburane® is indicated for both adults and pediatric patients suffering from urea cycle disorders, making it a versatile treatment option.
